This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tourmaline Bio Future Growth

Future criteria checks 0/6

Tourmaline Bio's earnings are forecast to decline at 22.2% per annum while its annual revenue is expected to grow at 76.9% per year. EPS is expected to decline by 8.3% per annum.

Key information

-22.2%

Earnings growth rate

-8.30%

EPS growth rate

Biotechs earnings growth	23.3%
Revenue growth rate	76.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	20 Oct 2025

Recent future growth updates

Recent updates

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Sep 09

Earnings and Revenue Growth Forecasts

NasdaqGS:TRML - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	10	-179	-141	N/A	5
12/31/2026	N/A	-121	-121	N/A	7
12/31/2025	N/A	-98	-95	N/A	7
6/30/2025	N/A	-88	-86	-86	N/A
3/31/2025	N/A	-83	-84	-84	N/A
12/31/2024	N/A	-73	-77	-77	N/A
9/30/2024	N/A	-64	-66	-66	N/A
6/30/2024	N/A	-49	-48	-48	N/A
3/31/2024	N/A	-48	-39	-39	N/A
12/31/2023	N/A	-42	-28	-28	N/A
9/30/2023	N/A	-34	-23	-23	N/A
6/30/2023	N/A	-31	-19	-19	N/A
3/31/2023	N/A	-27	-15	-10	N/A
12/31/2022	N/A	-20	-12	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRML is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRML is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRML is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRML is forecast to have no revenue next year.

High Growth Revenue: TRML is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRML's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/29 04:02
End of Day Share Price	2025/10/27 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tourmaline Bio, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joshua Schimmer	Cantor Fitzgerald & Co.
Daniil Gataulin	Chardan Capital Markets, LLC
Yatin Suneja	Guggenheim Securities, LLC

This company has been acquired

Tourmaline Bio Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 14% to US$48.39

Recent updates

Tourmaline Bio Requests Nasdaq Global Select Market to Suspend the Shares from Trading Effective October 28, 2025 and Remove the Shares from Listing on Nasdaq

Tourmaline Bio, Inc. Announces Management and Committee Changes

Novartis AG (SWX:NOVN) completed the acquisition of 92.94% in Tourmaline Bio, Inc. (NasdaqGS:TRML).

CFO & Treasurer exercised options to buy US$689k worth of stock.

Price target decreased by 14% to US$48.39

Buyout Of Tourmaline By Novartis Primarily On Pacibekitug IL-6 Novel Mode Of Action

Novartis AG (SWX:NOVN) entered into an agreement to acquire Tourmaline Bio, Inc. (NasdaqGS:TRML) for $1.2 billion.

Tourmaline Bio (NASDAQ:TRML) Is In A Good Position To Deliver On Growth Plans

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 Transit Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-Reactive Protein and Chronic Kidney Disease

Tourmaline Bio, Inc., Annual General Meeting, Jun 04, 2025

We're Not Very Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Rate

New major risk - Revenue and earnings growth

Tourmaline Bio, Inc. Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Tourmaline Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

High number of new and inexperienced directors

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Tourmaline Bio, Inc. Announces Resignation of Yung Chyung as Chief Medical Officer,Effective October 31, 2024

Tourmaline Bio, Inc. Announces Formation of Cardiovascular Scientific Advisory Board

New minor risk - Share price stability

Tourmaline Bio, Inc. Announces the Promotion of Ryan Robinson to Chief Financial Officer

Tourmaline Bio, Inc Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

Tourmaline Bio: Sinking On Rival's Stodgy Data - I'm Slightly Bearish

Tourmaline Bio, Inc. has filed a Follow-on Equity Offering.

Tourmaline Bio: Time For A Pause

Tourmaline Bio, Inc. Appoints Clay Siegall to Serve as a Director

Tourmaline Bio, Inc. Announces Resignation of Cariad Chester as Member of the Board of Directors

Co-Founder recently bought US$68k worth of stock

Co-Founder recently bought US$111k worth of stock

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from shareholders in a reverse merger transaction.